HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-alpha, IFN-beta and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21.

Abstract
Recent studies have revealed promising leads on the potential of interferons (IFNs) in combination with retinoids in solid tumor therapy. The role of IFN-alpha and retinoic acid (RA) in cervical cancer is currently under active study. Because preclinical and clinical data on IFN-beta in combination with retinoids show promising results against breast carcinoma, we analysed the anti-proliferative effect of human recombinant IFN-beta alone or in combination with all-trans RA on two human squamous cervical carcinoma cell (SCC) lines (ME180 and SiHa). The two cell lines differ in their sensitivity to the anti-proliferative effects of the different agents and their combination: i) both cell lines were more responsive to IFN-beta than to IFN-alpha2b; ii) combined treatment with RA increases the growth inhibitory effect of the single agents in ME180, but not in SiHa; iii) the antiproliferative effect correlates with the induction of apoptosis. We suggest as a possible mechanisms of action that interferon regulatory factor-1 (IRF-1), a transcription factor which belongs to the IFN machinery, and the cyclin-dependent kinase inhibitor (CDKi) p21 can be involved in cellular growth inhibition and in the induction of apoptosis. These results support the use of IFN-beta in further clinical investigation possibly in combination with retinoids.
AuthorsV Giandomenico, G Vaccari, G Fiorucci, Z Percario, S Vannuchi, P Matarrese, W Malorni, G Romeo, G R Affabris
JournalEuropean cytokine network (Eur Cytokine Netw) Vol. 9 Issue 4 Pg. 619-31 (Dec 1998) ISSN: 1148-5493 [Print] FRANCE
PMID9889406 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • CDKN1A protein, human
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclins
  • DNA-Binding Proteins
  • Enzyme Inhibitors
  • IRF1 protein, human
  • Interferon Regulatory Factor-1
  • Interferon-alpha
  • Phosphoproteins
  • RNA, Messenger
  • Recombinant Proteins
  • Tretinoin
  • Interferon-beta
  • interferon alfa-2b
  • Cyclin-Dependent Kinases
  • 2',5'-Oligoadenylate Synthetase
Topics
  • 2',5'-Oligoadenylate Synthetase (genetics)
  • Apoptosis (drug effects)
  • Carcinoma, Squamous Cell (metabolism, pathology, therapy)
  • Cell Division (drug effects)
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclin-Dependent Kinases (antagonists & inhibitors)
  • Cyclins (biosynthesis, genetics)
  • DNA Fragmentation (drug effects)
  • DNA-Binding Proteins (genetics, metabolism)
  • Drug Therapy, Combination
  • Enzyme Inhibitors (metabolism)
  • Female
  • Gene Expression (drug effects)
  • Humans
  • Interferon Regulatory Factor-1
  • Interferon-alpha (administration & dosage, therapeutic use)
  • Interferon-beta (administration & dosage, therapeutic use)
  • Phosphoproteins (genetics, metabolism)
  • RNA, Messenger (genetics, metabolism)
  • Recombinant Proteins
  • Tretinoin (administration & dosage, therapeutic use)
  • Tumor Cells, Cultured
  • Uterine Cervical Neoplasms (metabolism, pathology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: